A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines

BACKGROUND: Cancer heterogeneity poses a serious challenge concerning the toxicity and adverse effects of therapeutic inhibitors, especially when it comes to combinatorial therapies that involve multiple targeted inhibitors. In particular, in non-small cell lung cancer (NSCLC), a number of studies h...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yutao, Sharma, Amit, Wu, Xiaolong, Weiher, Hans, Skowasch, Dirk, Essler, Markus, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130779/
https://www.ncbi.nlm.nih.gov/pubmed/35646685
http://dx.doi.org/10.3389/fonc.2022.713476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130779/
https://www.ncbi.nlm.nih.gov/pubmed/35646685
http://dx.doi.org/10.3389/fonc.2022.713476

Ejemplares similares